UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 192

Sortiert nach

CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry

The Journal of pharmacology and experimental therapeutics, 2009-06, Vol.329 (3), p.938

2009

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update

Clinical pharmacology and therapeutics, 2021-02, Vol.109 (2), p.302-309

2021

Volltextzugriff (PDF)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations

Journal of personalized medicine, 2017-12, Vol.8 (1), p.1

2017

Volltextzugriff (PDF)

CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant

Molecular pharmacology, 2009-06, Vol.75 (6), p.1337-1346

2009

Volltextzugriff (PDF)

CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities

Current topics in medicinal chemistry, 2013-06, Vol.13 (12), p.1429

2013

Volltextzugriff (PDF)

Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra- and Inter-Species Differences in Drug Metabolism

DRUG METABOLISM AND PHARMACOKINETICS, 2011-01, Vol.26 (1), p.15-29

2011

Volltextzugriff (PDF)

Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients

PloS one, 2016-08, Vol.11 (8), p.e0161074-e0161074

2016

Volltextzugriff (PDF)

Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact

eLife, 2020-09, Vol.9

2020

Volltextzugriff (PDF)

Spotlight on CYP4B1

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2038

2023

Volltextzugriff (PDF)

Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol

Biochemical journal, 2015-01, Vol.465 (1), p.103-114

2015

Volltextzugriff (PDF)

Generation and characterization of a murine model of Bietti crystalline dystrophy

Investigative ophthalmology & visual science, 2014-09, Vol.55 (9), p.5572-5581

2014

Volltextzugriff (PDF)

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue

PLoS genetics, 2011-05, Vol.7 (5), p.e1002078

2011

Volltextzugriff (PDF)

Clinical Pharmacokinetic Assessment of Kratom ( Mitragyna speciosa ), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants

Pharmaceutics, 2022-03, Vol.14 (3), p.620

2022

Volltextzugriff (PDF)

Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition

Drug metabolism reviews, 2014-08, Vol.46 (3), p.247-260

2014

Volltextzugriff (PDF)

A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites

Blood, 2014-01, Vol.123 (4), p.582-589

2014

Volltextzugriff (PDF)

Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system

Pharmacogenetics and genomics, 2019-10, Vol.29 (8), p.192

2019

Volltextzugriff (PDF)

A new LC-MS assay for the quantitative analysis of vitamin K metabolites in human urine[S]

Journal of lipid research, 2019-04, Vol.60 (4), p.892-899

2019

Volltextzugriff (PDF)

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase

PloS one, 2014-10, Vol.9 (10), p.e110054-e110054

2014

Volltextzugriff (PDF)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity

Clinical and translational science, 2020-01, Vol.13 (1), p.147-156

2020

Volltextzugriff (PDF)

Developmental expression of human hepatic CYP2C9 and CYP2C19

The Journal of pharmacology and experimental therapeutics, 2004-03, Vol.308 (3), p.965

2004

Volltextzugriff (PDF)

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach

Clinical and translational science, 2022-02, Vol.15 (2), p.322-329

2022

Volltextzugriff (PDF)

Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population

PloS one, 2017-04, Vol.12 (4), p.e0173616

2017

Volltextzugriff (PDF)

Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents

PloS one, 2013-12, Vol.8 (12), p.e84582-e84582

2013

Volltextzugriff (PDF)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions

Clinical and translational science, 2020-09, Vol.13 (5), p.1004-1009

2020

Volltextzugriff (PDF)

There and Back Again: A Perspective on 20 Years of CYP4Z1

Drug metabolism and disposition, 2024-05, Vol.52 (6), p.498

2024

Volltextzugriff (PDF)

1 – 25 von 192

Suche als RSS-Feed

Aktive Filter

ThemaToxicology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(182)
Mit Volltextzugriff
(155)

Publikationsform

Artikel
(190)
Buchkapitel
(2)

Sprache

Englisch
(192)
Japanisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(134)
Humans
(118)
Pharmacology & Pharmacy
(76)
Biological And Medical Sciences
(51)
Animals
(41)
Medical Sciences
(40)
Male
(38)
Biochemistry & Molecular Biology
(36)
Pharmacology. Drug Treatments
(36)
Cytochrome P-450 Enzyme System - Metabolism
(35)
Female
(35)
Cytochrome P-450 Cyp2c9
(32)
Kinetics
(26)
Aryl Hydrocarbon Hydroxylases - Genetics
(23)
Cytochrome P-450 Enzyme System - Genetics
(23)
Cytochrome P450
(23)
Aryl Hydrocarbon Hydroxylases
(22)
Genotype
(22)
Middle Aged
(22)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations

CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant

CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities

Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra- and Inter-Species Differences in Drug Metabolism

Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients

Multiplexed measurement of variant abundance and activity reveals VKOR topology, active site and human variant impact

Spotlight on CYP4B1

Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol

Generation and characterization of a murine model of Bietti crystalline dystrophy

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue

Clinical Pharmacokinetic Assessment of Kratom ( Mitragyna speciosa ), a Botanical Product with Opioid-like Effects, in Healthy Adult Participants

Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition

A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites

Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system

A new LC-MS assay for the quantitative analysis of vitamin K metabolites in human urine[S]

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity

Developmental expression of human hepatic CYP2C9 and CYP2C19

Adapting regulatory drug‐drug interaction guidance to design clinical pharmacokinetic natural product‐drug interaction studies: A NaPDI Center recommended approach

Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population

Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions

There and Back Again: A Perspective on 20 Years of CYP4Z1

Aktive Filter

Suchergebnisse filtern